NCT06086912

A Clinical Study to Compare the Bioavailability of HR17031 in Healthy Subjects at Different Sites

A Single-center, Randomized, Open, Three-period, Three-sequence Crossover Clinical Study to Compare the Bioavailability and Safety of a Single Subcutaneous Injection of HR17031 in Healthy Subjects at Different Sites

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the bioavailability and safety of HR17031 injection in healthy subjects at different sites.

Conditions

• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	HR17031	Receive a single dose of HR17031 at every period (First period：abdomen. Second period. upper arm. Third period: thigh).
DRUG	HR17031	Receive a single dose of HR17031 at every period (First period：upper arm. Second period: thigh. Third period: abdomen).
DRUG	HR17031	Receive a single dose of HR17031 at every period (First period：thigh. Second period: abdomen. Third period: upper arm).

Timeline

• Start date: 2023-11-07
• Primary completion: 2023-12-12
• Completion: 2023-12-12
• First posted: 2023-10-17
• Last updated: 2024-02-01

Locations

1 site across 1 country: China